Clinical trialPhase 2Not yet recruiting
Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer
An Umbrella Clinical Trial of Antibody/Peptide-Drug Conjugates Matched by Mass Spectrometry-Based Absolute Quantitation of Proteins in Locally Advanced or Metastatic Pancreatic or Breast Cancer
- Outcome
- Ongoing
- Phase
- Phase 2
- Status
- Not yet recruiting
- Study type
- Interventional
- Start
- 10 September 2026
- Expected end
- 1 February 2030
- Enrollment
- 225 participants
- Sites
- 1
- Primary outcomes
- Objective Response Rate (ORR) as Assessed by RECIST 1.1
- Sponsor
- Other
- Results posted
- No
- Last update
- 17 September 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try